Advanced search

First case of drug eruption due to ipragliflozin: Case report and review of the literature.

Natsuko Saito-Sasaki, Yu Sawada, Daisuke Nishio, Motonobu Nakamura

Journal: The Australasian journal of dermatology 2018;58(3):236-238

PMID: 27242192

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Ipragliflozin is a new drug for the treatment of diabetes mellitus. Its action of sodium-glucose cotransporter 2 (SGLT2) inhibition induces glucosuria and decreases blood glucose levels. We report the first case of ipragliflozin-related eczematous drug eruption and a review of the past literature on drug eruptions caused by SGLT2 inhibitors.

© 2016 The Australasian College of Dermatologists.

Address: Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
DOI: 10.1111/ajd.12502

Link outs

Free resources

Medical:

Other Literature Sources:

Miscellaneous:

Subscription / membership required

Full Text Sources:

MeSH Terms: Aged, Diabetes Mellitus, Drug Eruptions, Glucosides, Humans, Hypoglycemic Agents, Male, Thiophenes
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.